Overview

A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation.

Status:
Not yet recruiting

Trial end date:
2028-06-30

Target enrollment:

Participant gender:

Summary

A phase II, single-arm, open-label study evaluating efficacy, safety and feasibility of combined chemotherapy and pembrolizumab as first line therapy and Osimertinib as second line therapy in advanced non squamous NSCLC adult patients with epidermal growth factor receptor (EGFR) exon 21 point mutation and programmed cell death receptor ligand 1 (PD-L1) positive.

Phase:

Phase 2

Details

Lead Sponsor:

Peking Union Medical College Hospital

Treatments:

Osimertinib
Pembrolizumab
Pemetrexed